Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Sanofi Earnings Slashed in First Quarter

By Pharmaceutical Processing | May 2, 2013

Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.

Sanofi’s net profit was €1 billion ($1.3 billion) in the January-March quarter, down 45 percent from €1.8 billion a year earlier.

Revenue from Plavix, which had been the world’s second best-selling drug until its U.S. patent expired last May, slid 5 percent. That, along with generic competition that cut sales of blood pressure drugs Avapro and Aprovel by 20.8 percent, dragged down total company sales by 5.3 percent.

Sanofi warned that core earnings per share could fall up to 5 percent this year, after a 12.8 percent drop in 2012. It warned also that growth would not return until the second half of 2013.

“As expected the loss of exclusivitiy of Plavix, Avapro and Eloxatin in the course of 2012 in the U.S. had a negative impact on Q1 results,” CEO Christopher Viehbacher said in a statement.

The €1.22 per share was well below the €1.33 average forecast of analysts polled by FactSet.

Sanofi’s weak earnings came as other pharmaceutical giants also delivered gloomy first quarter reports. Pfizer Inc. fell short of Wall Street expectations and lowered its profit and sales forecasts for the year this week, while last week Bristol-Myers Squibb Co. posted a 45 percent drop in first-quarter profit on plunging sales from increased generic competition.

Sanofi played up strong performances in its diabetes, vaccines and biotechnology company Genzyme, but that was more than offset by a €553 million in lost sales from heightened generic competition for drugs Eloxatin, Lovenox, Plavix and Aprovel.

Sales in Western Europe and the United States, markets that account for over half of Sanofi’s total sales, fell by about 10 percent in the first quarter.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE